Are BCG-induced non-specific effects adequate to provide protection against COVID-19?

Are BCG-induced non-specific effects adequate to provide protection against COVID-19?

The world is experiencing a pandemic of Coronavirus Disease (COVID-19) caused by type-2 Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2). Vaccination is the only option to prevent future surges of the disease. Efforts for developing an effective vaccine are underway, but the timeline for t...

Full description

Bibliographic Details
Main Author:	Vipin M. Vashishtha
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2021-01-01
Series:	Human Vaccines & Immunotherapeutics
Subjects:	coronavirus disease sars-cov-2 bacillus calmette-guerin (bcg) vaccine nonspecific effects trained innate immunity
Online Access:	http://dx.doi.org/10.1080/21645515.2020.1794219

Similar Items

The impact of Bacillus Calmette-Guérin (BCG) vaccination on the course of COVID-19
by: Jakub Krzysztof Gałązka
Published: (2022-10-01)

The Potential Roles of BCG Vaccine in the Prevention or Treatment of COVID-19
by: Jie Wang, et al.
Published: (2022-05-01)

A single strain of Mycobacterium bovis bacillus Calmette-Guérin (BCG) grown in two different media evokes distinct humoral immune responses in mice
by: V.L. Petricevich, et al.
Published: (2001-01-01)

Characterizing the BCG Induced Macrophage and Neutrophil Mechanisms for Defense Against Mycobacterium tuberculosis
by: Thomas E. Bickett, et al.
Published: (2020-06-01)

Disseminated BCG sepsis following intravesical therapy for Bladder Carcinoma: A case report and review of literature
by: Oreoluwa Oladiran, et al.
Published: (2020-03-01)

Previous BCG vaccination is associated with less severe clinical progression of COVID-19
by: Susan Martins Pereira, et al.
Published: (2023-04-01)

Lessons from Bacillus Calmette-Guérin: Harnessing Trained Immunity for Vaccine Development
by: Samuel T. Pasco, et al.
Published: (2020-09-01)

Vaccination-related Mycobacterium bovis BCG Infection
by: Anna Liberek, et al.
Published: (2006-05-01)

BCG Vaccine—The Road Not Taken
by: Coad Thomas Dow, et al.
Published: (2022-09-01)

Higher BCG‐induced trained immunity prevalence predicts protection from COVID‐19: Implications for ongoing BCG trials
by: Samer Singh, et al.
Published: (2022-06-01)

Grupo Técnico de Estudos do BCG em Câncer Vacina BCG (Bacillus Calmette-Guérin)
by: Humberto Torloni, et al.
Published: (2023-08-01)

Impact of BCG vaccination and metabolic risk factors on the severity of SARS-Cov-2 infection: a cross-sectional study from a tertiary care centre in northern India
by: N. N. Begam, et al.
Published: (2022-07-01)

The Diverse Applications of Recombinant BCG-Based Vaccines to Target Infectious Diseases Other Than Tuberculosis: An Overview
by: Esma Mouhoub, et al.
Published: (2021-10-01)

Carcinoma In Situ (CIS): Is There a Difference in Efficacy between Various BCG Strains? A Comprehensive Review of the Literature
by: Andres Llano, et al.
Published: (2024-01-01)

Evolution of the Bacillus Calmette-Guérin scar Russia and Moreau strains in newborns: A brazilian cohort
by: Ramon Andrade de Souza, et al.
Published: (2023-08-01)

Perianal Plasmoacanthoma After BCG-Immunotherapy: Case Report and Review of Literature
by: Masoumeh Roohaninasab, et al.
Published: (2022-07-01)

Immunological Hallmarks for Clinical Response to BCG in Bladder Cancer
by: Chun Jye Lim, et al.
Published: (2021-01-01)

Report of 16 Years of the BCG Vaccine under the Expanded Program on Immunizations in Mexico (2006–2021)
by: Rodrigo Romero-Feregrino, et al.
Published: (2023-02-01)

Determinants of BCG scarification among children in rural Guinea-Bissau: A prospective cohort study
by: Katarina M. Funch, et al.
Published: (2018-10-01)

Case Report: BCG-Triggered Hemophagocytic Lymphohistiocytosis in an Infant With X-Linked Recessive Mendelian Susceptibility to Mycobacterial Disease Due to a Variant of Chronic Granulomatous Disease
by: Suleiman Al-Hammadi, et al.
Published: (2021-06-01)

Asymptomatic renal BCG granulomatosis: An unusual complication of intravesical BCG therapy for carcinoma urinary bladder
by: Suresh Bhat, et al.
Published: (2015-01-01)

Research progress on specific and non-specific immune effects of BCG and the possibility of BCG protection against COVID-19
by: Jingli Du, et al.
Published: (2023-01-01)

The safety of BCG revaccination in the context of COVID-19
by: Adriana Sánchez-García, et al.
Published: (2023-12-01)

DISSEMINATED BACILLUS-CALMETTE-GUÉRIN INFECTIONS AND PRIMARY IMMUNODEFICIENCY DISORDERS IN SINGAPORE: A SINGLE CENTER 15-YEAR RETROSPECTIVE REVIEW
by: Rina Yue Ling Ong, et al.
Published: (2020-08-01)

Establishment of an in vitro model of monocyte-like THP-1 cells for trained immunity induced by bacillus Calmette-Guérin
by: Jin-Chuan Xu, et al.
Published: (2024-04-01)

Disseminated Bacillus Calmette–Guérin (BCG) infection and acute exacerbation of interstitial pneumonitis: an autopsy case report and literature review
by: Gen Shimizu, et al.
Published: (2020-09-01)

COVID-19 and Beyond: Exploring Public Health Benefits from Non-Specific Effects of BCG Vaccination
by: Kent J. Koster, et al.
Published: (2021-10-01)

BCG lymphadenopathy detected in a BCG-vaccinated infant
by: A.S. Barouni, et al.
Published: (2004-05-01)

A case of Mycobacterium bovis Bacillus Calmette-Guérin (BCG) strain meningitis and ventriculitis following BCG vaccination
by: Mihoko Furuichi, et al.
Published: (2020-11-01)

BCG Vaccination and the Risk of Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis
by: Parnian Jamshidi, et al.
Published: (2023-04-01)

Evaluation of Children with Complication of BCG Vaccination in North of Iran
by: Mohammad Sadegh Rezai, et al.
Published: (2017-03-01)

Systematic review and meta-analysis of the current evidence on the duration of protection by bacillus Calmette–Guérin vaccination against tuberculosis
by: I Abubakar, et al.
Published: (2013-09-01)

Integrating Non-human Primate, Human, and Mathematical Studies to Determine the Influence of BCG Timing on H56 Vaccine Outcomes
by: Louis R. Joslyn, et al.
Published: (2018-08-01)

Mycobacterium bovis Osteomyelitis of the Thoracic Spine Mimicking a Metastatic Lytic Lesion in a Patient Exposed to Intravesicular Bacille Calmette-Guérin Treatment
by: Jessica R. Newman, et al.
Published: (2014-07-01)

Breast abscess due to Bacillus Calmette-Guérin
by: Aurélien Dinh, et al.
Published: (2017-06-01)

BCG mediated protection of the lung against experimental SARS-CoV-2 infection
by: Kerry L. Hilligan, et al.
Published: (2023-09-01)

BCG and SARS-CoV-2—What Have We Learned?
by: Jakub Kulesza, et al.
Published: (2022-09-01)

First vaccination after birth: serious adverse events of Bacillus Calmette-Guérin (BCG) in real-world
by: Jinmiao Lu, et al.
Published: (2022-11-01)

Mycotic aortic aneurysm due to intravesical BCG immunotherapy: Clinical manifestations and diagnostic challenges
by: Brittany J Holmes, et al.
Published: (2014-01-01)

An Investigation into Improvement of Stability and Efficacy of Intravesical BCG Formulations Using Freeze-Drying Technique
by: Hamidreza Hozouri, et al.
Published: (2021-01-01)